前列腺癌淋巴结寡复发:解剖模式与手术及放疗模板的关系
本研究回顾性分析82例前列腺癌生化复发患者,将158个淋巴结复发灶映射到参考CT及不同手术和放疗模板上。结果显示49%复发仅位于真骨盆,22%位于所有模板之外;ENRT覆盖优于除超扩大sLND外的所有手术模板,但至少31%患者无法被任何模板挽救。
要点
- 过半淋巴结复发位于真骨盆外,局限或标准扩大sLND不足。
- ENRT覆盖优于除超扩大sLND外的所有手术模板。
- 22%病灶位于所有模板外,至少31%患者无法被任何模板覆盖。
核心结论
- 超过一半的淋巴结复发位于真骨盆外,局限或标准扩大sLND作为挽救治疗不充分且不推荐。
- 为最大化疗效,应优先选择ENRT或超扩大sLND。
研究设计与样本
- 回顾性分析纳入82例原发前列腺癌治疗后生化复发且18F-胆碱PET/CT显示≤5个淋巴结复发(N1/M1a)的患者。
- 将158个淋巴结复发灶(N1:88;M1a:70)映射到参考患者CT及不同手术模板(限于超扩大)和改编的PIVOTAL ENRT模板上进行比较。
主要发现
- 49%患者复发仅位于真骨盆,10%位于髂总淋巴结,10%位于腹膜后/腹股沟淋巴结,31%为组合位置。
- ENRT与手术模板间体积重叠高达40%。
- ENRT完全覆盖的患者比例更高(p<0.02),覆盖病灶总数更多(p<0.001),优于所有类型sLND,但与超扩大sLND相当(患者水平p=0.6;病灶水平p=0.09)。
- 158个病灶中22%位于所有模板之外(N1:7%;M1a:15%),至少31%的82例患者无法被任何模板挽救。
临床怎么用
- 对于淋巴结寡复发(≤5个)患者,不推荐使用局限或标准扩大sLND作为挽救治疗。
- 应优先考虑ENRT或超扩大sLND以最大化覆盖复发灶。
- 需注意部分病灶位于所有模板外,治疗决策应个体化。
局限性
- 回顾性分析设计。
- 样本量有限(82例患者,158个病灶)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with biochemical recurrence following primary prostate cancer (PCa) treatment often experience relapse in the lymph nodes (LNs). Both salvage LN dissection (sLND) and elective nodal radiotherapy (ENRT) are potential treatment options. OBJECTIVE: To describe anatomic patterns of nodal oligorecurrent PCa in relation to different surgical and radiotherapy templates. DESIGN, SETTING, AND PARTICIPANTS: Patients with biochemical recurrence following primary PCa treatment were eligible for 18F-choline positron emission tomography/computed tomography (CT). Patients with five or fewer LN recurrences (N1/M1a) were eligible for the current retrospective analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: All LN recurrences were mapped on a reference patient CT, as well as different surgical templates (limited to superextended) and an adapted version of the PIVOTAL ENRT template, blinded for the recurrences. Descriptive statistics were used to report recurrences in relation to the different templates and to compare LN coverage between templates. RESULTS AND LIMITATIONS: In total, 158 LN recurrences (N1: 88; M1a: 70) in 82 patients (median age: 67yr; prostate-specific antigen [PSA]: 3.1ng/ml; PSA doubling time of 7.8mo at the time of clinical recurrence) were mapped. In 49% of patients, recurrences were exclusively located in the true pelvis, followed by the common iliac LN (10%), retroperitoneal/inguinal LN (10%), or a combination (31%). There was up to 40% volume overlap between ENRT and the surgical templates. Theoretically, with ENRT more patients are fully covered (p<0.02) and the total number of covered lesions is higher (p<0.001) when compared to all types of sLND, except for superextended sLND, which is comparable to ENRT (patient-level: p=0.6; lesion-level: p=0.09). With 22% of all 158 lesions located outside all templates (N1: 7%; M1a: 15%), at least 31% of all 82 patients would not be salvaged using any of the templates. CONCLUSIONS: More than half of nodal recurrences are located outside the true pelvis. Limited or standard extended sLND is considered insufficient as a salvage treatment approach and is thus not recommended for use. To maximize treatment outcomes for nodal recurrences, ENRT or superextended sLND should be preferred. PATIENT SUMMARY: We compared two possible treatment options, elective nodal radiotherapy and salvage lymph node dissection, for patients with prostate cancer recurrence limited to five or fewer lymph nodes and reported the nodal distrubution. Radiotherapy and surgery cover different areas with possible different outcomes.
引用
- De Bruycker A, De Bleser E, Decaestecker K, et al. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. Eur Urol. 2018. PMID: 30503072. doi:10.1016/j.eururo.2018.10.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。